{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:44:57Z","timestamp":1792514697016,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jdcr.2026.08.046","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:55:25Z","timestamp":1788566125000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Deucravacitinib in concomitant psoriasis vulgaris and bullous pemphigoid: A case of sustained dual disease control"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1078-157X","authenticated-orcid":false,"given":"Rachel","family":"Daher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Magnatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Landini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Verdelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jdcr.2026.08.046_bib1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.046_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010328","article-title":"The intriguing links between psoriasis and bullous pemphigoid","volume":"12","author":"Maronese","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jdcr.2026.08.046_bib3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jdcr.2026.08.046_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fmed.2020.00511","article-title":"The bidirectional Association between bullous pemphigoid and psoriasis: a population-based cohort Study","volume":"7","author":"Kridin","year":"2020","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.046_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ajd.12899","article-title":"Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies","volume":"60","author":"Phan","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jdcr.2026.08.046_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jdcr.2026.08.046_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.jdcr.2026.08.046_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jdcr.2026.08.046_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jdcr.2026.08.046_bib10","doi-asserted-by":"crossref","DOI":"10.2147\/CCID.S606758","article-title":"Bullous pemphigoid possibly induced by deucravacitinib in a patient with psoriasis","volume":"19","author":"Lu","year":"2026","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626005448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:29:29Z","timestamp":1790864969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"alternative-id":["S2352512626005448"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.046","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deucravacitinib in concomitant psoriasis vulgaris and bullous pemphigoid: A case of sustained dual disease control","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}